Al Rubaie Khalid, Espinoza Juan V, Lasave Andres F, Savino-Zari Dario, Arevalo Fernando A, Arevalo J Fernando
King Khaled Eye Specialist Hospital, Al-Oruba Street, P.O. Box 7191, Riyadh 11462, Saudi Arabia.
The Retina & Vitreous Service, Clínica Oftalmológica Centro Caracas, Avenida Panteon, Caracas 1010, Venezuela.
Case Rep Ophthalmol Med. 2014;2014:592746. doi: 10.1155/2014/592746. Epub 2014 Nov 17.
Objective. To report the visual and anatomic outcomes of pneumatic displacement with perfluoropropane (C3F8) gas and intravitreal tissue plasminogen activator (IVTPA) for subretinal subfoveal hemorrhage after focal laser photocoagulation in central serous chorioretinopathy (CSCR). Method. Interventional, retrospective case report of one eye (one patient). Outcome measures included visual acuity (VA), central macular thickness (CMT), and size of the lesion at two weeks of followup. Fluorescein angiography (FA) and optical coherent tomography (OCT) were used to measure anatomic outcomes. Results. A 35-year-old man with history of chronic CSCR received focal laser photocoagulation in the right eye two days before presentation. At initial examination, VA was 20/200 (ETDRS chart), CMT was 398 μ, and a subretinal subfoveal hemorrhage was seen. Tissue plasminogen activator (tPA) at a dose of 25 µg/0.1 mL was injected intravitreally before intravitreal C3F8 injection, and prone positioning was indicated postoperatively. At 24 hours, the hemorrhage had been displaced inferiorly and VA improved to 20/100. Two weeks later, VA improved to 20/80, CMT decreased to 225 μ, and the hemorrhage decreased without foveal involvement. Conclusions. The technique seems safe and effective in treating visually significant subretinal subfoveal hemorrhage.
目的。报告在中心性浆液性脉络膜视网膜病变(CSCR)中,使用全氟丙烷(C3F8)气体和玻璃体内组织型纤溶酶原激活剂(IVTPA)进行气体置换治疗黄斑中心凹下视网膜下出血的视觉和解剖学结果。方法。对一只眼(一名患者)进行的介入性回顾性病例报告。观察指标包括随访两周时的视力(VA)、中心黄斑厚度(CMT)和病变大小。使用荧光素血管造影(FA)和光学相干断层扫描(OCT)测量解剖学结果。结果。一名有慢性CSCR病史的35岁男性在就诊前两天右眼接受了局部激光光凝治疗。初次检查时,视力为20/200(ETDRS视力表),CMT为398μm,可见黄斑中心凹下视网膜下出血。在玻璃体内注射C3F8之前,先向玻璃体内注射25μg/0.1mL的组织型纤溶酶原激活剂(tPA),术后采取俯卧位。24小时时,出血已向下移位,视力提高到20/100。两周后,视力提高到20/80,CMT降至225μm,出血减少且未累及黄斑中心凹。结论。该技术在治疗具有明显视觉影响的黄斑中心凹下视网膜下出血方面似乎安全有效。